Edition:
United States

Insmed Inc (INSM.OQ)

INSM.OQ on NASDAQ Stock Exchange Global Select Market

27.61USD
25 May 2018
Change (% chg)

$0.21 (+0.77%)
Prev Close
$27.40
Open
$27.27
Day's High
$27.92
Day's Low
$27.09
Volume
161,054
Avg. Vol
283,496
52-wk High
$33.94
52-wk Low
$11.49

Chart for

About

Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment... (more)

Overall

Beta: 1.00
Market Cap(Mil.): $2,115.56
Shares Outstanding(Mil.): 76.62
Dividend: --
Yield (%): --

Financials

  INSM.OQ Industry Sector
P/E (TTM): -- 238.69 33.30
EPS (TTM): -3.16 -- --
ROI: -48.87 -7.54 13.04
ROE: -80.41 -10.33 14.90

BRIEF-Insmed Announces FDA Acceptance For Filing Of NDA For Lung Disease Treatment

* INSMED ANNOUNCES FDA ACCEPTANCE FOR FILING OF NEW DRUG APPLICATION FOR ALIS IN NTM LUNG DISEASE CAUSED BY MAC

May 16 2018

BRIEF-Insmed Reports Q1 Loss Per Share $0.89

* INSMED REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

May 02 2018

BRIEF-Insmed Inc Submits NDA To FDA For ALIS

* INSMED SUBMITS NEW DRUG APPLICATION TO FDA FOR ALIS IN NTM LUNG DISEASE CAUSED BY MAC

Mar 29 2018

BRIEF-Insmed Reports Q4 Loss Per Share $0.85

* INSMED REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Feb 23 2018

BRIEF-Insmed Prices Public Offering Of $400 Mln Principal Amount Of Its Convertible Senior Notes

* INSMED ANNOUNCES PRICING OF PUBLIC OFFERING OF CONVERTIBLE SENIOR NOTES

Jan 24 2018

BRIEF-Insmed Announces Proposed Public Offering Of Convertible Senior Notes

* INSMED ANNOUNCES PROPOSED PUBLIC OFFERING OF CONVERTIBLE SENIOR NOTES

Jan 22 2018

Competitors

Earnings vs. Estimates